2018-06-07 08:15
The event be webcasted on www.smabolagsdagen.net. The presentation will be available on the company’s website after the presentation. For full program and registration, see link. (https://www.aktiespararna.se/smabolagsdagen) More information: Anders...
2018-06-04 10:00
The results are presented in collaboration with AstraZeneca and globally renowned oncologists from EU, US and Canada. By analyzing a blood sample DiviTum provides key information for upfront identification of therapy resistant patients and enables non-invasive...
2018-05-17 09:15
DiviTum® measures the activity of serum thymidine kinase (TK) activity which plays a critical role in DNA synthesis and cell proliferation. The study found that serum TK is a circulating prognostic and monitoring marker in patients with advanced breast...
2018-05-03 08:00
Pontus Nobréus will initially be based in Sweden. Pontus will be responsible for global business development, which includes sales, commercialization and customer strategy. He will be part of the management team at Biovica. "I'm looking...
2018-04-27 11:46
The subsidiary Biovica Inc is a sales company based in Delaware. The purpose of the US subsidiary is to establish DiviTum on the US market. DiviTum measures cell proliferation rate and the objective is to provide information regarding treatment efficacy...
2018-04-24 10:08
In accordance with the above guidelines, the Nomination Committee for the 2018 Annual General Meeting will consist of the following persons: The members of the Nomination Committee together represent approximately 33 percent of the shares and 47 percent...
2018-04-17 08:30
The study, presented at the ongoing AACR congress in Chicago, concluded that using DiviTum to measure cell proliferation in blood samples could potentially be used to assess cell cycle modulation by Ibrance®. “We are pleased that DiviTum is...
2018-03-28 08:00
The study, consisting of 31 patients with metastatic breast cancer, was performed at the Prato Hospital, Italy. The results are published in the scientific journal Oncotarget and demonstrates that DiviTum can evaluate efficacy of standard hormonal therapy...
2018-03-20 08:00
The value of the order is approximately 100 000 USD. "New and more effective cancer treatment are important in order to improve patient outcome. At the same time, it’s expensive to develop new cancer drugs. With DiviTum, we aim to provide value...
2018-02-22 11:53
100 women with metastasized breast cancer will be included in the study, with the objective to find markers to identify early development of resistance of today's standard treatment in combination with Ibrance®. By early identification of women...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects